Form 4: Veracyte CFO Sells 15,275 Shares Under 10b5-1 Plan

Veracyte's Chief Financial Officer, Rebecca Chambers, sold 15,275 shares of common stock at an average price of $38.3413 per share, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Rebecca Chambers, the Chief Financial Officer of Veracyte, Inc., executed a sale of 15,275 shares of the company's common stock on November 12, 2024.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2024.
• The average sale price was $38.3413 per share, with individual sale prices ranging from $38.04 to $38.78.
• Following the transaction, Ms. Chambers directly owns 124,501 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to a pre-planned stock sale by an executive. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard practice among publicly traded companies to allow insiders to sell shares without the appearance of trading on non-public information.
• The sale by the CFO is not unusual and is similar to transactions by executives at comparable companies such as Exact Sciences (EXAS) and Genomic Health (GHDX) before its acquisition by Exact Sciences.
• These types of transactions are regularly disclosed via SEC Form 4 filings.

Stakeholder Impact

• The sale of shares by the CFO may have a minor impact on the stock price, but it is unlikely to be significant given the pre-planned nature of the transaction.

Key Dates

Keywords

Veracyte, VCYT, insider trading, Form 4, Rule 10b5-1, stock sale, Rebecca Chambers, CFO, executive compensation